Investors have already subscribed to buy all 800,000 shares offered. The vast majority of investors valued the value of the Pill share at the maximum possible indicative value. Almost three quarters of investors valued Pilulka shares with 424 crowns, while Pilulka expected to sell securities in the range of 325 to 425 crowns. That is why the Pill can already count on more than 300 million crowns.
“From the beginning, we were very optimistic and received a very positive response from investors and brokers. In our opinion, the pill is a great company that has further success and growth ahead of it. And visibly, not only we think so, “said Martin Kasa, co-founder of the Pill, adding that great interest also means great commitment.
–
–
Kasa did not want to comment on whether Pikulka would offer another action. “Our goal now is to fulfill the promises we have made to investors. The first public subscription of shares has been employed by the company’s management in recent weeks, but we are also focusing on our business all the time, ”said Kasa.
According to him, the pill awaits the most important part of the year, even without the influence of a pandemic, which multiplies everything. “We now want to focus mainly on the management of the company and properly serve all customers. Now is the time for further steps and considerations, “he added.
Book of orders for the purchase of shares @Pilulkacz was published today at 10:00. The vast majority is at a maximum value of CZK 424 per share in a total volume of over 500,000 shares in this value. Thank you for the trust of all interested parties. ???? https://t.co/zgfqO5hgsH
– Martin Kasa (@martin_kasa) October 13, 2020
Petr Kováč, partner for corporate finance at EY, also evaluates the Positive public subscription of the Pill. “Interest in the Pill exceeded expectations. What will be the final price of the share, but I do not want to estimate yet, because there are still a few days until the subscription closes. The activity of investors at the end of the subscription has its dynamics, which makes it almost impossible to estimate the price, ”says Kováč.
The pill earned 1.6 billion crowns in the first half of the year, up 45 percent year-on-year. It is currently operating in the Czech Republic and Slovakia, while in Romania it remains in the red due to high investments.
–
–
The Prague Stock Exchange Start has been operating since 2017 and is aimed at smaller companies in particular. Recently, for example, it has attracted the development company eMan. For example, the leather processor KARO Invest or the developer Udi have already entered this market.
The largest pharmacy network in the Czech Republic is Dr. Max from the Penta group, which operates 460 branches. Last year, the company’s sales in the Czech Republic rose by 11.5 percent year on year to 20 billion crowns. In total, according to the data of the State Institute for Drug Control, there are over 2,500 pharmacies on the Czech market. They earn around 70 billion crowns a year for medicines and medical devices.
–
–
– .
